Beta-amyloid peptide (Abeta), the major constituent of amyloid plaques in the brains of Alzheimer's patients, is thought to be the cause of Alzheimer's Disease (AD)1-3. AD is the most common neurodegenerative disease and afflicts about 10% of the population over 604. Using a proprietary production technique that limits the peptide's conformational changes, rPeptide has produced an ammonium hydroxide beta amyloid counter-ion. The Abeta ammonium hydroxide product can be utilized for in vitro aggregation experiments as well as cell based assays.